Viral Vector Packaging with Transient Silencing for Cytotoxic Transgenes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of viral vectors carrying certain transgenes, particularly those that are cytotoxic or incompatible with viral vector packaging systems, faces challenges such as low titer or no production due to interference with viral packaging processes.
Innovation Solution
Introducing a second nucleic acid capable of expressing an interfering nucleic acid, such as short-hairpin RNAs (shRNAs) or artificial miRNAs (amiRNAs), to specifically inhibit transgene expression during the vector packaging process, thereby allowing for efficient production of viral vectors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transgene expression is allowed during viral vector packaging, then the viral vectors can carry functional transgenes, but the transgene products interfere with viral packaging leading to low titer or no production
Solution Approach 1:
The patent introduces an interfering nucleic acid (such as shRNA or amiRNA) that specifically targets and degrades the transgene mRNA during the packaging process. This preliminary action prevents transgene expression at the mRNA level, allowing viral vectors to be produced at high titers. After packaging is complete, the interfering nucleic acid is no longer present or active, allowing the transgene to be expressed in the target cells. This resolves the contradiction by temporarily suppressing transgene expression only when necessary for packaging.
2Productivity
If interfering nucleic acid is introduced to inhibit transgene expression, then viral vector production efficiency increases, but the system complexity increases due to additional nucleic acid components
Solution Approach 1:
The patent uses an interfering nucleic acid (shRNA or amiRNA) as an intermediary molecule that mediates between the transgene and the packaging system. This intermediary specifically binds to and degrades transgene mRNA, preventing harmful transgene expression during packaging without directly interfering with viral vector assembly. The intermediary approach allows efficient packaging while maintaining system manageability through specific molecular recognition.
3Productivity
If transgene expression is completely suppressed, then viral packaging is efficient, but the transgene cannot be expressed even after packaging
Solution Approach 1:
The patent implements periodic or transient suppression of transgene expression using interfering nucleic acids that are active only during the packaging phase. The interfering nucleic acid is introduced temporarily and degrades transgene mRNA during packaging, then is removed or becomes inactive afterward. This periodic action pattern allows transgene expression to be suppressed when needed for packaging efficiency, then restored for functional expression in target cells, resolving the contradiction between packaging efficiency and transgene functionality.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of high-titer and functional viral vectors, even those carrying cytotoxic or incompatible transgenes, by transiently silencing transgene expression during the packaging process.
Implementation Method 1
abolishing transgene expression by RNA degradation (e.g., as mediated by short-hairpin RNAs (shRNAs), artificial miRNAs (amiRNAs), etc.) during the vector packaging process
Data Source
AI summary
In some aspects, the disclosure relates to methods for improving titer and yield of viral vector production. In some embodiments, the methods comprise transient silencing of transgene expression during packaging of a viral vector.